Slingshot members are tracking this event:
Merck (MRK) Expects to File NDA for DPP-4 Inhibitor Omarigliptin in Treatment of Type 2 Diabetes by End of 2016 - Cancelled
Slingshot Insights Explained
Apr 08, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Nda, Dpp-4 Inhibitor, Omarigliptin, Type 2 Diabetes